In a decision with far-reaching implications for European Union procurement law, contractual enforcement, and public health governance, a Belgian court has ordered Poland and Romania to take delivery of approximately €1.9 billion worth of COVID-19 vaccines from Pfizer Inc. The ruling represents a decisive judicial endorsement of binding obligations arising from centralised EU vaccine procurement agreements and underscores the limits of unilateral withdrawal by Member States in the aftermath of the pandemic.
The dispute originates from a multi year supply agreement concluded between the European Commission and Pfizer during the height of the COVID-19 pandemic. Under this framework, Member States committed to the collective procurement of vaccine doses, with delivery schedules extending over several years. The contractual architecture was designed to ensure equitable access, pricing stability, and coordinated public health responses across the Union.
However, by April 2022, as the pandemic evolved and vaccination demand declined, Poland refused to honour its obligations under the agreement. Romania subsequently adopted a similar position. Both states sought to justify their refusal on a combination of changed circumstances, including the reduced urgency of mass vaccination campaigns, the economic and logistical consequences of the war in Ukraine, and allegations that Pfizer had abused a dominant market position.
In late 2023, Pfizer initiated legal proceedings in Belgium, invoking jurisdiction on the basis of the contractual framework governing the agreement. The pharmaceutical company sought enforcement of the delivery and payment obligations, arguing that the commitments entered into by Member States under the EU coordinated procurement mechanism were legally binding and not subject to unilateral repudiation.
The Belgian court has now unequivocally sided with Pfizer. It rejected the arguments advanced by Poland and Romania, holding that the evolution of the pandemic and broader geopolitical developments did not extinguish contractual liability. The court further declined to entertain claims of abuse of dominant position in this context, effectively reinforcing the primacy of contractual certainty over post hoc policy reconsiderations.
The judgment imposes substantial financial obligations on both states. Poland has been ordered to take delivery of vaccine doses valued at approximately €1.3 billion, while Romania must accept doses worth around €600 million. Together, these commitments amount to roughly $2.2 billion, representing one of the most significant post pandemic enforcement actions involving pharmaceutical supply contracts within the European Union. Notably, the ruling mandates both delivery and payment, signalling that Member States cannot evade liability by refusing physical acceptance of goods once contractual triggers have been activated.
From a doctrinal perspective, the case raises critical questions regarding the applicability of force majeure and the doctrine of frustration in long term public procurement contracts. Poland’s reliance on the war in Ukraine and shifting pandemic dynamics appears to have been insufficient to meet the high threshold required to discharge contractual obligations under European private law principles.
Equally significant is the court’s treatment of allegations concerning abuse of dominant position. While such claims typically fall within the ambit of EU competition law, the court’s rejection suggests that the contractual framework, negotiated at a supranational level, was not deemed susceptible to challenge on competition grounds in this instance. This may reflect judicial deference to the extraordinary circumstances under which the agreements were concluded, as well as the institutional role of the European Commission in structuring the procurement process.
The ruling carries profound implications for the balance between EU level coordination and Member State sovereignty. By enforcing the terms of a centrally negotiated contract, the Belgian court has effectively reaffirmed the binding nature of collective commitments made under EU mechanisms, even in the face of shifting domestic priorities.
This outcome may serve as a precedent for future disputes involving joint procurement, particularly in sectors such as energy, defence, and critical medical supplies. It also raises questions about risk allocation in emergency contracting, especially where demand forecasts and public health conditions evolve rapidly.
At the time of reporting, Poland’s health ministry had not issued an official response to the judgment, while the Romanian government indicated that it had not yet received formal notification and was therefore unable to comment. This measured silence suggests that both governments may be assessing legal options, including potential appeals, while simultaneously evaluating the fiscal and logistical implications of compliance.
The Belgian court’s decision marks a defining moment in the legal aftermath of the COVID-19 pandemic. It underscores that emergency driven procurement agreements, even when concluded under unprecedented global pressure, retain their binding force and are enforceable through judicial mechanisms.
For policymakers, legal practitioners, and multinational corporations alike, the ruling serves as a powerful reminder that contractual commitments made within the EU framework are not merely political instruments but legally enforceable obligations. As Europe continues to navigate the long tail of the pandemic, this judgment is likely to shape the contours of public procurement law and cross border contractual enforcement for years to come.